caffeine has been researched along with paroxetine in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (15.00) | 18.2507 |
| 2000's | 8 (40.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brøsen, K; Gram, LF; Jeppesen, U; Loft, S; Poulsen, HE; Vistisen, K | 1 |
| Herrmann, N; Kalow, W; Naranjo, CA; Ozdemir, V; Reed, K; Sellers, EM; Shulman, RW | 1 |
| Bell, CJ; Malizia, AL; Nutt, DJ | 1 |
| Kato, S; Nishida, S; Nisijima, K; Shioda, K | 1 |
| Hori, H; Mitoma, M; Miyamoto, K; Nakamura, J; Sugita, A; Ueda, N; Umene, W; Yoshimura, R | 1 |
| Fujitani, K; Hara, A; Hoshino, M; Iguchi, K; Ishii, N; Nagano, H; Nagashima, T; Shimoi, K; Takamori, N; Tanida, N; Unno, K; Yamamoto, H | 1 |
| Dimpfel, W | 1 |
2 review(s) available for caffeine and paroxetine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Brain mechanisms of social anxiety disorder.
Topics: Animals; Brain; Caffeine; Carbon Dioxide; Cholecystokinin; Dopamine; Fear; Fenfluramine; Humans; Panic Disorder; Paroxetine; Phobic Disorders; Piperazines; Rats; Ritanserin; Selective Serotonin Reuptake Inhibitors; Serotonin; Tomography, Emission-Computed | 1998 |
2 trial(s) available for caffeine and paroxetine
| Article | Year |
|---|---|
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Caffeine; Chromatography, High Pressure Liquid; Citalopram; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Male; Mephenytoin; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sparteine | 1996 |
Effects of acute paroxetine treatment on the consumption of cigarette smoking and caffeine in depressed patients.
Topics: Adult; Aged; Caffeine; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Cotinine; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Methoxyhydroxyphenylglycol; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Smoking; Tobacco Use Disorder; Treatment Outcome | 2007 |
16 other study(ies) available for caffeine and paroxetine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Female; Fluvoxamine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1998 |
Possible serotonin syndrome arising from an interaction between caffeine and serotonergic antidepressants.
Topics: Adult; Amoxapine; Caffeine; Central Nervous System Stimulants; Drug Interactions; Female; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Suicide, Attempted | 2004 |
Ingestion of theanine, an amino acid in tea, suppresses psychosocial stress in mice.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Caffeine; Circadian Rhythm; Corticosterone; Glutamates; Housing, Animal; Hypertrophy; Hypothalamo-Hypophyseal System; Male; Mice; Organ Size; Paroxetine; Pituitary-Adrenal System; Social Dominance; Stress, Psychological; Tea | 2013 |
Pharmacological classification of herbal extracts by means of comparison to spectral EEG signatures induced by synthetic drugs in the freely moving rat.
Topics: Animals; Brain; Caffeine; Electroencephalography; Magnoliopsida; Methylphenidate; Paroxetine; Phenytoin; Plant Extracts; Rats; Tramadol | 2013 |